Shots:

• The two global companies will supply up to ~60M doses of a vaccine to the UK’s government to combat COVID-19
• Sanofi leads the clinical development and registration of the vaccine and expects a P-I/II study to be initiated in Sept’2020- followed by a P-III study by the end of 2020. Additionally- the companies are expecting the approval in H1’21
• The vaccine is deploying Sanofi’s S-protein COVID-19 antigen together with GSK’s adjuvant technology. Both the companies are scaling up manufacturing of the antigen and adjuvant to produce up to 1B doses per year

­ Ref: Sanofi | Image: Sanofi